|
| 36917923 | eIF4F translation initiation complex, a predictive marker of response to immunotherapy in mucosal melanoma. | | 2023 |
| 36162037 | Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). | Journal of Clinical Oncology | 2023 |
| 36425794 | Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73Â weeks. | JAAD International | 2023 |
| 36403367 | Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle. | European Journal of Cancer | 2023 |
| 37749382 | Drug-tolerant persister cells in cancer: the cutting edges and future directions. | | 2023 |
| 37748398 | Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology. | | 2023 |
| 37594336 | Concomitant medication use does not appear to alter long-term efficacy of sonidegib for advanced basal cell carcinoma: a post hoc analysis based on the 42-month BOLT study. | Eur J Dermatol | 2023 |
| 37579248 | Systemic Therapy for Melanoma: ASCO Guideline Update. | J Clin Oncol | 2023 |
| 37710354 | Serious immune-related upper gastrointestinal toxicity of immune checkpoint inhibitors: a multicenter case series. | | 2023 |
| 37793215 | Immune checkpoint inhibitors-associated myocarditis without cardiovascular symptoms. | | 2023 |
| 37625239 | Secondary hypertrophic osteoarthropathy revealing a metastatic melanoma. | | 2023 |
| 38057799 | Immune checkpoints are predominantly co-expressed by clonally expanded CD4FoxP3 intratumoral T-cells in primary human cancers. | | 2023 |
| 37348035 | Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. | J Clin Oncol | 2023 |
| 36717341 | [Use of genome-wide testing in oncology: French expert opinion based on the Delphi methodology]. | | 2023 |
| 36516188 | Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1. | | 2023 |
| 37277264 | Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. | | 2023 |
| 36578099 | Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors. | | 2023 |
| 37142601 | Genomic mutation landscape of skin cancers from DNA repair-deficient xeroderma pigmentosum patients. | Nat Commun | 2023 |
| 37018924 | Efficacy of ipilimumab 3Â mg/kg following progression on low-dose ipilimumab in metastatic melanoma. | | 2023 |
| 36762421 | Post-transcriptional polyadenylation site cleavage maintains 3'-end processing upon DNA damage. | | 2023 |
| 37459873 | Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. | Lancet Oncol | 2023 |
| 37266890 | Cured or Not? Long-term Outcomes of Immunotherapy Responders. Focus on Melanoma. | | 2023 |
| 37193799 | Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. | Nat Med | 2023 |
| 37442495 | Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors. | Crit Rev Oncol Hematol | 2023 |
| 36868570 | Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma. | J Immunother Cancer | 2023 |
| 36477181 | Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. | Clin Cancer Res | 2023 |
| 37309702 | COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF. | Future Oncol | 2023 |
| 36473326 | Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors. | European Journal of Cancer | 2023 |
| 36739633 | Tenofovir-induced osteoporosis fracture in a patient using PrEP: A pitfall for the oncologist. | | 2023 |
| 36460017 | Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF<sup>V600</sup> mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. | Lancet Oncol | 2023 |
| 36789267 | Spatial patterns of the cap-binding complex eIF4F in human melanoma cells. | | 2023 |
| 37506329 | Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. | J Clin Oncol | 2023 |
| 36979460 | Elevated Soluble TNF-Receptor 1 in the Serum of Predementia Subjects with Cerebral Small Vessel Disease. | | 2023 |
| 35120598 | Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. | Cancer Cell | 2022 |
| 36307149 | Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy. | Journal for ImmunoTherapy of Cancer | 2022 |
| 36170791 | An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases. | European Journal of Cancer | 2022 |
| 36035132 | FMRP, a multifunctional RNA-binding protein in quest of a new identity. | Frontiers in Genetics | 2022 |
| 35565428 | Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. | Cancers (Basel) | 2022 |
| 35998515 | Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias. | | 2022 |
| 35940183 | Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. | Lancet Oncol | 2022 |
| 35874918 | Neuropilin-1 cooperates with PD-1 in CD8 TÂ cells predicting outcomes in melanoma patients treated with anti-PD1. | iScience | 2022 |
| 35740604 | Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma. | Cancers | 2022 |
| 36270461 | Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Annals of Oncology | 2022 |
| 36207413 | The multiple roles of LDH in cancer. | Nat Rev Clin Oncol | 2022 |
| 36332438 | High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. | European Journal of Cancer | 2022 |
| 36202690 | Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. | Eur J Cancer | 2022 |
| 36265502 | Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. | Lancet Oncol | 2022 |
| 35862871 | COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With <i>BRAF</i> V600-Mutant Melanoma. | J Clin Oncol | 2022 |
| 35793872 | Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma. | J Immunother Cancer | 2022 |
| 35728875 | Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). | J Immunother Cancer | 2022 |